Wednesday 30th March 2016
Halfway Point Marked in Scleroderma Patient Enrolment for Cytori's ECCS-50 Phase 3 Trial
Cytori Therapeutics has enrolled and treated its 40th patient with scleroderma in the Phase 3 STAR clinical trial for ECCS-50, marking 50 percent of target enrollment.